Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Channing J Der

Showing results (201-210 of 236) with videos related to

Pageof 24
Sort By:
Science Signaling|December 19, 2023
RHOA<sup>L57V</sup> drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signalingAntje Schaefer, Richard G Hodge, Haisheng Zhang, et al.
Plos Medicine|July 21, 2010
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinomaJeran K Stratford, David J Bentrem, Judy M Anderson, et al.
Cancer Cell|January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth SuppressionTikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Cell Reports|July 27, 2017
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor EvolutionGrace R Anderson, Peter S Winter, Kevin H Lin, et al.
Cancer Cell|November 14, 2018
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory MechanismAngelina V Vaseva, Devon R Blake, Thomas S K Gilbert, et al.
Nature Communications|November 4, 2022
Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translationBartosz Mucha, Shuo Qie, Sagar Bajpai, et al.
NPJ Precision Oncology|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancersDaniel P Nussbaum, Colin A Martz, Andrew M Waters, et al.
Cancer Research|April 29, 2026
KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic CancerRavi Thakur, Dezhen Wang, Tuo Hu, et al.
Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Pageof 24

Showing results (201-210 of 236) with videos related to

Sort By:
Pageof 24
Science Signaling|December 19, 2023
RHOA<sup>L57V</sup> drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signalingAntje Schaefer, Richard G Hodge, Haisheng Zhang, et al.
Plos Medicine|July 21, 2010
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinomaJeran K Stratford, David J Bentrem, Judy M Anderson, et al.
Cancer Cell|January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth SuppressionTikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Cell Reports|July 27, 2017
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor EvolutionGrace R Anderson, Peter S Winter, Kevin H Lin, et al.
Cancer Cell|November 14, 2018
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory MechanismAngelina V Vaseva, Devon R Blake, Thomas S K Gilbert, et al.
Nature Communications|November 4, 2022
Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translationBartosz Mucha, Shuo Qie, Sagar Bajpai, et al.
NPJ Precision Oncology|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancersDaniel P Nussbaum, Colin A Martz, Andrew M Waters, et al.
Cancer Research|April 29, 2026
KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic CancerRavi Thakur, Dezhen Wang, Tuo Hu, et al.
Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Pageof 24